Tonix Pharmaceuticals Bets on Sleep to Tackle Major Depressive Disorder

BERKELEY HEIGHTS, N.J. – June 29, 2026

Tonix Pharmaceuticals has initiated a significant strategic expansion, enrolling the first patient in a Phase 2 clinical trial aimed at repositioning its recently approved fibromyalgia drug for the vast major depressive disorder (MDD) market. The HORIZON study will evaluate TNX-102 SL, a novel sublingual formulation of cyclobenzaprine, as a first-line monotherapy for adults with MDD, marking a pivotal step in the company's strategy to leverage its core assets across multiple high-need central nervous system (CNS) conditions. This move signals a potential shift in depression treatment, focusing on the critical, often-overlooked role of disturbed sleep in the disorder.

A New Horizon for Depression Treatment

Major depressive disorder is a pervasive and debilitating illness affecting more than 21 million adults in the U.S. annually. For decades, the standard of care has revolved around medications like SSRIs and SNRIs, which modulate serotonin and norepinephrine levels. However, these treatments come with significant limitations. Up to 70% of patients fail to achieve full remission with initial therapy, and nearly 60% discontinue treatment due to burdensome side effects, including sexual dysfunction, weight gain, and, ironically, further sleep disruption.

This is where Tonix sees a critical opening. An overwhelming 90% of individuals with MDD suffer from sleep disturbances, a symptom that is not just a consequence of depression but a perpetuating factor. Poor sleep can precede the onset of depression and is a strong predictor of relapse. "Many current therapies are associated with tolerability and adherence challenges," noted Dr. Gregory Sullivan, Chief Medical Officer of Tonix Pharmaceuticals. He emphasized that TNX-102 SL is designed to directly address this gap by targeting the quality of sleep, particularly the deep slow-wave sleep essential for nightly neuro-restoration.

The HORIZON trial, a 6-week, double-blind, placebo-controlled study, will enroll approximately 360 patients across 30 U.S. sites. Its primary goal is to measure the change in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale (MADRS), a standard clinical benchmark. Success in this potentially pivotal study could validate a sleep-centric approach as a viable and much-needed first-line option for MDD.

A Strategic Play to Maximize Value

This expansion into the MDD market is a calculated strategic shift for Tonix, which recently transitioned into a commercial-stage company. Its lead asset, TNX-102 SL, was approved by the FDA in August 2025 and launched commercially as TONMYA® for the treatment of fibromyalgia—the first new drug for that condition in over 15 years. The early commercial performance has been promising, with the company reporting approximately $3.7 million in revenue from TONMYA in its first full quarter and securing market access for over 52 million commercially insured lives.

By pursuing an MDD indication for an already-approved drug, Tonix is employing an efficient and de-risked development strategy. The established safety, tolerability, and manufacturing processes for TNX-102 SL provide a significant advantage over developing a new chemical entity from scratch. This allows the company to leverage its existing investment and clinical knowledge to target a market substantially larger than fibromyalgia.

"We are committed to extending the science of TNX-102 SL into other conditions in which disturbed sleep quality plays important roles, including MDD," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. This vision is supported by a strong financial foundation. As of its latest report, the company held $185.5 million in cash and equivalents with no debt, providing a runway to fund the HORIZON study and other pipeline advancements well into 2027.

The Science of Targeting Sleep

The scientific rationale for using TNX-102 SL in depression is rooted in its unique mechanism and formulation. Cyclobenzaprine, a tricyclic compound, is a potent antagonist at multiple neuronal receptors—specifically the 5-HT2A serotonergic, α1-adrenergic, and H1-histaminergic receptors—that are crucial in regulating sleep architecture.

Unlike the oral form of cyclobenzaprine, which is primarily known as a muscle relaxant, Tonix’s proprietary sublingual formulation allows for rapid absorption into the bloodstream. This bypasses the liver's first-pass metabolism, which not only speeds onset of action for bedtime dosing but also reduces the formation of norcyclobenzaprine, a long-lasting metabolite associated with next-day drowsiness. The goal is to improve sleep quality without impairing daytime function.

The hypothesis has already been supported by promising signals from previous clinical trials. In two Phase 3 studies for fibromyalgia and a Phase 2 study for post-traumatic stress disorder (PTSD), TNX-102 SL demonstrated improvements not only in the primary conditions but also in subjective sleep quality and depressive symptoms. According to one neuropsychiatry expert not involved in the study, targeting 5-HT2A receptors is a validated mechanism for increasing restorative slow-wave sleep, and improving sleep architecture is increasingly seen as a direct pathway to alleviating mood symptoms.

Navigating a Shifting Competitive Landscape

Tonix enters the MDD space at a time of intense innovation. The treatment paradigm is moving beyond traditional monoamine-based antidepressants toward novel mechanisms. Competitors are advancing drugs that target the glutamatergic system (like the approved Auvelity and Spravato), the orexin system for arousal and wakefulness (such as Janssen's seltorexant), and the GABAergic system (like Sage's zuranolone).

However, TNX-102 SL is uniquely positioned. While many novel agents are being developed as adjunctive therapies for treatment-resistant patients, Tonix is aiming for a first-line monotherapy indication. Its primary focus on restoring sleep quality as the therapeutic driver also sets it apart. While other drugs may improve sleep as a secondary benefit, it is the central hypothesis of the HORIZON study. If successful, TNX-102 SL could offer a compelling alternative for newly diagnosed patients, particularly the large subset whose depression is intertwined with severe sleep disturbance, providing a new tool for clinicians and fresh hope for patients seeking effective relief without the difficult side effects of current standards.